CLINICAL STUDIES
Comparative study of ACE-inhibition, angiotensin II antagonism, and calcium channel blockade on flow-mediated vasodilation in patients with coronary disease (BANFF study)
Todd J. Anderson, MD*,
Eleanor Elstein, MD, BSc ,
Harry Haber, MPH and
François Charbonneau, MD, MSc
* Cardiovascular Division, Department of Medicine, University of Calgary, Calgary, Alberta, Canada
McGill University, Montreal, Quebec, Canada
Parke-Davis, Ann Arbor, Michigan, USA
Manuscript received March 12, 1999;
revised manuscript received August 6, 1999,
accepted October 12, 1999.
Reprint requests and correspondence: Dr. Todd J. Anderson, Foothills Hospital, 1403-29th Street N.W., Calgary, AB Canada T2N-2T9
todd.anderson{at}crha-health.ab.ca
OBJECTIVES
To determine the effect of angiotensin-converting enzyme (ACE) inhibition on brachial flow-mediated vasodilation.
BACKGROUND
Quinapril, an ACE inhibitor with high affinity, has been shown to improve coronary endothelial dysfunction in patients with coronary artery disease. The effectiveness of different vasoactive agents to improve human endothelial function is unknown.
METHODS
High resolution ultrasound was used to assess endothelium-dependent brachial artery flow-mediated vasodilation (FMD) in patients with coronary disease. We studied 80 patients (mean age 58 ± 0.9 years) in a partial-block, cross-over design trial. Patients were randomized to one of four different drug sequences to receive quinapril 20 mg, enalapril 10 mg, losartan 50 mg or amlodipine 5 mg daily. Each patient received three drugs with a two-week washout period between treatments. The primary end point was the absolute difference in FMD after eight weeks of each study drug compared with their respective baselines analyzed in a blinded fashion.
RESULTS
There was mild impairment of FMD at baseline (7.3 ± 0.6%). The change in FMD from baseline was significant only for quinapril (1.8 ± 1%, p < 0.02). No change was seen with losartan (0.8 ± 1.1%, p = 0.57), amlodipine (0.3 ± 0.9%, p = 0.97) or enalapril (–0.2 ± 0.8%, p = 0.84). No significant change in nitroglycerin-induced dilation occurred with drug therapy. The improvement in quinapril response was not seen in those with the DD ACE genotype (0.5 ± 2.1%) but was seen in those with the ID and II genotype (3.3 ± 1.2 and 3.2 ± 1.9%, respectively, p = 0.03).
CONCLUSION
Only quinapril was associated with significant improvement in FMD, and this response is related to the presence of the insertion allele of the ACE genotype.
|
Abbreviations and Acronyms
| | ACE | = angiotensin-converting enzyme | | ANCOVA | = analysis of covariance | | FMD | = flow-mediated vasodilation | | NO | = nitric oxide | | NTG | = nitroglycerin |
|
This article has been cited by other articles:
|
|
|
|
 
L. M Title, E. Lonn, F. Charbonneau, M. Fung, K. J Mather, S. Verma, and T. J Anderson
Relationship between brachial artery flow-mediated dilatation, hyperemic shear stress, and the metabolic syndrome
Vascular Medicine,
November 1, 2008;
13(4):
263 - 270.
[Abstract]
[PDF]
|
|
|
|
|
|
|
M. Kosch, A. Levers, D. Lang, V. Bartels, K. H. Rahn, H. Pavenstadt, and M. Hausberg
A randomized, double-blind study of valsartan versus metoprolol on arterial distensibility and endothelial function in essential hypertension
Nephrol. Dial. Transplant.,
July 1, 2008;
23(7):
2280 - 2285.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Balzer, T. Rassaf, C. Heiss, P. Kleinbongard, T. Lauer, M. Merx, N. Heussen, H. B. Gross, C. L. Keen, H. Schroeter, et al.
Sustained benefits in vascular function through flavanol-containing cocoa in medicated diabetic patients a double-masked, randomized, controlled trial.
J. Am. Coll. Cardiol.,
June 3, 2008;
51(22):
2141 - 2149.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Imamura, R. Takahashi, R. Murakami, H. Kataoka, X. W. Cheng, Y. Numaguchi, T. Murohara, and K. Okumura
The effects of endothelial nitric oxide synthase gene polymorphisms on endothelial function and metabolic risk factors in healthy subjects: the significance of plasma adiponectin levels
Eur. J. Endocrinol.,
February 1, 2008;
158(2):
189 - 195.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. J Vittorio, K. Ahuja, M. Kasper, H. Turalic, C.-H. Tseng, U. P Jorde, and C. Gor
Comparison of high- versus low-tissue affinity ACE-inhibitor treatment on circulating aldosterone levels in patients with chronic heart failure
Journal of Renin-Angiotensin-Aldosterone System,
December 1, 2007;
8(4):
200 - 204.
[Abstract]
[PDF]
|
|
|
|
|
|
|
S. Heeneman, J. C. Sluimer, and M. J.A.P. Daemen
Angiotensin-Converting Enzyme and Vascular Remodeling
Circ. Res.,
August 31, 2007;
101(5):
441 - 454.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. J. Miller, L. E. Norton, M. P. Murphy, M. C. Dalsing, and J. L. Unthank
The role of the renin-angiotensin system and oxidative stress in spontaneously hypertensive rat mesenteric collateral growth impairment
Am J Physiol Heart Circ Physiol,
May 1, 2007;
292(5):
H2523 - H2531.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Suessenbacher, M. Frick, H. F Alber, V. Barbieri, O. Pachinger, and F. Weidinger
Association of improvement of brachial artery flow-mediated vasodilation with cardiovascular events
Vascular Medicine,
November 1, 2006;
11(4):
239 - 244.
[Abstract]
[PDF]
|
|
|
|
|
|
|
E. R. Schwarz, S. Rastogi, V. Kapur, N. Sulemanjee, and J. J. Rodriguez
Erectile Dysfunction in Heart Failure Patients
J. Am. Coll. Cardiol.,
September 19, 2006;
48(6):
1111 - 1119.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. H. Strauss and A. S. Hall
Angiotensin Receptor Blockers May Increase Risk of Myocardial Infarction: Unraveling the ARB-MI Paradox
Circulation,
August 22, 2006;
114(8):
838 - 854.
[Full Text]
[PDF]
|
|
|
|
|
|
|
W.-W. Su, S.-T. Cheng, T.-S. Hsu, and W.-J. Ho
Abnormal flow-mediated vasodilation in normal-tension glaucoma using a noninvasive determination for peripheral endothelial dysfunction.
Invest. Ophthalmol. Vis. Sci.,
August 1, 2006;
47(8):
3390 - 3394.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. M Yunker, J. S Parboosingh, H. E Conradson, P. Faris, P. J Bridge, J. Buithieu, L. M Title, F. Charbonneau, S. Verma, E. M Lonn, et al.
The effect of iron status on vascular health
Vascular Medicine,
May 1, 2006;
11(2):
85 - 91.
[Abstract]
[PDF]
|
|
|
|
|
|
|
N. Danchin, M. Cucherat, C. Thuillez, E. Durand, Z. Kadri, and P. G. Steg
Angiotensin-Converting Enzyme Inhibitors in Patients With Coronary Artery Disease and Absence of Heart Failure or Left Ventricular Systolic Dysfunction: An Overview of Long-term Randomized Controlled Trials.
Arch Intern Med,
April 10, 2006;
166(7):
787 - 796.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Erzen, P. Gradisek, P. Poredos, and M. Sabovic
Treatment of Essential Arterial Hypertension with Enalapril Does Not Result in Normalization of Endothelial Dysfunction of the Conduit Arteries
Angiology,
March 1, 2006;
57(2):
187 - 192.
[Abstract]
[PDF]
|
|
|
|
|
|
|
J Trevelyan, E W A Needham, A Morris, and R K Mattu
Comparison of the effect of enalapril and losartan in conjunction with surgical coronary revascularisation versus revascularisation alone on systemic endothelial function
Heart,
August 1, 2005;
91(8):
1053 - 1057.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. T. Yan, T. J. Anderson, F. Charbonneau, L. Title, S. Verma, E. Lonn, and on behalf of the FATE Investigators
Relationship Between Carotid Artery Intima-Media Thickness and Brachial Artery Flow-Mediated Dilation in Middle-Aged Healthy Men
J. Am. Coll. Cardiol.,
June 21, 2005;
45(12):
1980 - 1986.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. L. Lazar
Role of Angiotensin-Converting Enzyme Inhibitors in the Coronary Artery Bypass Patient
Ann. Thorac. Surg.,
March 1, 2005;
79(3):
1081 - 1089.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. L. Bots, J. Westerink, T. J. Rabelink, and E. J.P. de Koning
Assessment of flow-mediated vasodilatation (FMD) of the brachial artery: effects of technical aspects of the FMD measurement on the FMD response
Eur. Heart J.,
February 2, 2005;
26(4):
363 - 368.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Verma, C.-H. Wang, E. Lonn, F. Charbonneau, J. Buithieu, L. M. Title, M. Fung, S. Edworthy, A. C. Robertson, T. J. Anderson, et al.
Cross-sectional evaluation of brachial artery flow-mediated vasodilation and C-reactive protein in healthy individuals
Eur. Heart J.,
October 1, 2004;
25(19):
1754 - 1760.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Fathi, B. Haluska, N. Isbel, L. Short, and T. H. Marwick
The relative importance of vascular structure and function in predicting cardiovascular events
J. Am. Coll. Cardiol.,
February 18, 2004;
43(4):
616 - 623.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. W. Lissin, R. Oka, S. Lakshmi, and J. P Cooke
Isoflavones improve vascular reactivity in post-menopausal women with hypercholesterolemia
Vascular Medicine,
February 1, 2004;
9(1):
26 - 30.
[Abstract]
[PDF]
|
|
|
|
|
|
|
C. J. Pepine, J.-L. Rouleau, K. Annis, A. Ducharme, P. Ma, J. Lenis, R. Davies, U. Thadani, B. Chaitman, H. E. Haber, et al.
Effects of angiotensin-converting enzyme inhibition on transient ischemia: The quinapril anti-ischemia and symptoms of angina reduction (QUASAR) trial
J. Am. Coll. Cardiol.,
December 17, 2003;
42(12):
2049 - 2059.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. M. Title, K. Giddens, M. M. McInerney, M. J. McQueen, and B. A. Nassar
Effect of cyclooxygenase-2 inhibition with rofecoxib on endothelial dysfunction and inflammatory markers in patients with coronary artery disease
J. Am. Coll. Cardiol.,
November 19, 2003;
42(10):
1747 - 1753.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Arroyo-Espliguero, N. Mollichelli, P. Avanzas, E. Zouridakis, V. R Newey, D. K Nassiri, and J. C. Kaski
Chronic inflammation and increased arterial stiffness in patients with cardiac syndrome X
Eur. Heart J.,
November 2, 2003;
24(22):
2006 - 2011.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. T Hirsch and D. Duprez
The potential role of angiotensin-converting enzyme inhibition in peripheral arterial disease
Vascular Medicine,
November 1, 2003;
8(4):
273 - 278.
[Abstract]
[PDF]
|
|
|
|
|
|
|
S. Verma, M. R. Buchanan, and T. J. Anderson
Endothelial Function Testing as a Biomarker of Vascular Disease
Circulation,
October 28, 2003;
108(17):
2054 - 2059.
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. Aumegeat, N. Lamblin, P. de Groote, E. P. Mc Fadden, A. Millaire, C. Bauters, and J.-M. Lablanche
Aspirin Does Not Adversely Affect Survival in Patients With Stable Congestive Heart Failure Treated With Angiotensin-Converting Enzyme Inhibitors
Chest,
October 1, 2003;
124(4):
1250 - 1258.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. K. Koh, J. Y. Ahn, S. H. Han, D. S. Kim, D. K. Jin, H. S. Kim, M.-S. Shin, T. H. Ahn, I. S. Choi, and E. K. Shin
Pleiotropic effects of angiotensin II receptor blocker in hypertensive patients
J. Am. Coll. Cardiol.,
September 3, 2003;
42(5):
905 - 910.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. M. Lowson
Nitric Oxide Signaling and Clinical Alternatives to Nitric Oxide
Seminars in Cardiothoracic and Vascular Anesthesia,
September 1, 2003;
7(3):
239 - 252.
[Abstract]
[PDF]
|
|
|
|
|
|
|
M. A Schmidt, A. K Chakrabarti, C. Kehrer, D. Pfeninnger, R. D Brook, N. Kaciroti, C. Duvernoy, A. A Killeen, and S. Rajagopalan
Interactive effects of the ACE DD polymorphism with the NOS III homozygous G849T (Glu298->Asp) variant in determining endothelial function in coronary artery disease
Vascular Medicine,
August 1, 2003;
8(3):
177 - 183.
[Abstract]
[PDF]
|
|
|
|
|
|
|
D. S. Jacoby and D. J. Rader
Renin-Angiotensin System and Atherothrombotic Disease: From Genes to Treatment
Arch Intern Med,
May 26, 2003;
163(10):
1155 - 1164.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. J. Anderson, J. Hubacek, D. G. Wyse, and M. L. Knudtson
Effect of chelation therapy on endothelial function in patients with coronary artery disease: PATCH substudy
J. Am. Coll. Cardiol.,
February 5, 2003;
41(3):
420 - 425.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. O. Bonetti, L. O. Lerman, and A. Lerman
Endothelial Dysfunction: A Marker of Atherosclerotic Risk
Arterioscler. Thromb. Vasc. Biol.,
February 1, 2003;
23(2):
168 - 175.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Enseleit, T.F. Luscher, and F. Ruschitzka
Angiotensin-converting enzyme inhibition and endothelial dysfunction: focus on ramipril
Eur. Heart J. Suppl.,
January 1, 2003;
5(suppl_A):
A31 - A36.
[Abstract]
[PDF]
|
|
|
|
|
|
|
C-K Wong and H D White
Relation between blood pressure after an acute coronary event and subsequent cardiovascular risk
Heart,
December 1, 2002;
88(6):
555 - 558.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. E. Deanfield, J.-M. Detry, P. Sellier, P. R. Lichtlen, E. Thaulow, J. Bultas, C. Brennan, S. T. Young, B. Beckerman, and CAPE II Trial Investigators
Medical treatment of myocardial ischemia in coronary artery disease: effect of drug regime and irregular dosing in the CAPE II trial
J. Am. Coll. Cardiol.,
September 4, 2002;
40(5):
917 - 925.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Gokce, M. Holbrook, L. M. Hunter, J. Palmisano, E. Vigalok, J. F. Keaney Jr, and J. A. Vita
Acute effects of vasoactive drug treatment on brachial artery reactivity
J. Am. Coll. Cardiol.,
August 21, 2002;
40(4):
761 - 765.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. G. Modena, L. Bonetti, F. Coppi, F. Bursi, and R. Rossi
Prognostic role of reversible endothelial dysfunction in hypertensive postmenopausal women
J. Am. Coll. Cardiol.,
August 7, 2002;
40(3):
505 - 510.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. R Chiong and A. B Miller
Review: Renin-angiotensin system antagonism and lipid-lowering therapy in cardiovascular risk management
Journal of Renin-Angiotensin-Aldosterone System,
June 1, 2002;
3(2):
96 - 102.
[Abstract]
[PDF]
|
|
|
|
|
|
|
O. Lorenzo, M. Ruiz-Ortega, Y. Suzuki, M. Ruperez, V. Esteban, T. Sugaya, and J. Egido
Angiotensin III Activates Nuclear Transcription Factor-{kappa}B in Cultured Mesangial Cells Mainly via AT2 Receptors: Studies with AT1 Receptor-Knockout Mice
J. Am. Soc. Nephrol.,
May 1, 2002;
13(5):
1162 - 1171.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Ko, A. Maitland, P. W.M. Fedak, A. S. Dumont, M. Badiwala, F. Lovren, C. R. Triggle, T. J. Anderson, V. Rao, and S. Verma
Endothelin blockade potentiates endothelial protective effects of ace inhibitors in saphenous veins
Ann. Thorac. Surg.,
April 1, 2002;
73(4):
1185 - 1188.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Verma and T. J. Anderson
Fundamentals of Endothelial Function for the Clinical Cardiologist
Circulation,
February 5, 2002;
105(5):
546 - 549.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. C. Corretti, T. J. Anderson, E. J. Benjamin, D. Celermajer, F. Charbonneau, M. A. Creager, J. Deanfield, H. Drexler, M. Gerhard-Herman, D. Herrington, et al.
Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: A report of the International Brachial Artery Reactivity Task Force
J. Am. Coll. Cardiol.,
January 16, 2002;
39(2):
257 - 265.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Kelm
Flow-mediated dilatation in human circulation: diagnostic and therapeutic aspects
Am J Physiol Heart Circ Physiol,
January 1, 2002;
282(1):
H1 - H5.
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y.-p. Sun, B.-q. Zhu, A. E. M. Browne, S. Pulukurthy, T. M. Chou, K. Sudhir, S. A. Glantz, P. C. Deedwania, K. Chatterjee, and W. W. Parmley
Comparative Effects of ACE Inhibitors and an Angiotensin Receptor Blocker on Atherosclerosis and Vascular Function
Journal of Cardiovascular Pharmacology and Therapeutics,
June 1, 2001;
6(2):
175 - 181.
[Abstract]
[PDF]
|
|
|
|
|
|
|
M. Sanada, Y. Higashi, K. Nakagawa, S. Sasaki, I. Kodama, M. Tsuda, N. Nagai, and K. Ohama
Relationship between the angiotensin-converting enzyme genotype and the forearm vasodilator response to estrogen replacement therapy in postmenopausal women
J. Am. Coll. Cardiol.,
May 1, 2001;
37(6):
1529 - 1535.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Omland, W. Johnson, M. B. Gordon, and M. A. Creager
Endothelial function during stimulation of renin-angiotensin system by low-sodium diet in humans
Am J Physiol Heart Circ Physiol,
May 1, 2001;
280(5):
H2248 - H2254.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. J. Dzau
Tissue Angiotensin and Pathobiology of Vascular Disease : A Unifying Hypothesis
Hypertension,
April 1, 2001;
37(4):
1047 - 1052.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Hornig, U. Landmesser, C. Kohler, D. Ahlersmann, S. Spiekermann, A. Christoph, H. Tatge, and H. Drexler
Comparative Effect of ACE Inhibition and Angiotensin II Type 1 Receptor Antagonism on Bioavailability of Nitric Oxide in Patients With Coronary Artery Disease : Role of Superoxide Dismutase
Circulation,
February 13, 2001;
103(6):
799 - 805.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. H. O'Keefe, M. Wetzel, R. R. Moe, K. Brosnahan, and C. J. Lavie
Should an angiotensin-converting enzyme inhibitor be standard therapy for patients with atherosclerotic disease?
J. Am. Coll. Cardiol.,
January 1, 2001;
37(1):
1 - 8.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. M. A. van Ampting, M. L. Hijmering, J. J. Beutler, R. E. van Etten, H. A. Koomans, T. J. Rabelink, and E. S. G. Stroes
Vascular Effects of ACE Inhibition Independent of the Renin-Angiotensin System in Hypertensive Renovascular Disease : A Randomized, Double-Blind, Crossover Trial
Hypertension,
January 1, 2001;
37(1):
40 - 45.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C.-L. Chao and Y.-T. Lee
Impairment of Cerebrovascular Reactivity by Methionine-Induced Hyperhomocysteinemia and Amelioration by Quinapril Treatment
Stroke,
December 1, 2000;
31(12):
2907 - 2911.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Shechter, M. Sharir, M. J. P. Labrador, J. Forrester, B. Silver, and C. N. Bairey Merz
Oral Magnesium Therapy Improves Endothelial Function in Patients With Coronary Artery Disease
Circulation,
November 7, 2000;
102(19):
2353 - 2358.
[Abstract]
[Full Text]
[PDF]
| |
